Insights Into Prostate Cancer 2024
Perspectives on drivers in treatment decisions in the management of prostate cancer
Faculty Chair
Mehmet Asim Bilen, MD
Winship Cancer Institute, Atlanta, GA, USA
Faculty Chair
Alan Bryce, MD
City of Hope Cancer Center, Phoenix, AZ, USA
Faculty Chair
Amitkumar Mehta, MD
University of Alabama, Birmingham, AL, USA
Faculty Chair
Patrick Pilié, MD
MD Anderson Cancer Cancer, Houston, TX, USA
Faculty Chair
Vivek Narayan, MD
Penn Medicine, Philadelphia, PA, USA
Faculty Chair
Russell Z. Szmulewitz, MD
UChicago Medicine, Chicago, IL, USA
Faculty Chair
Russell Szmulewitz, MD
University of Chicago Medical Center, Chicago, IL, USA
Faculty Chair
Rana McKay, MD
UC San Diego Health, San Diego, CA, USA
Faculty Chair
Mehmet A. Bilen, MD
Winship Cancer Institute of Emory University, Atlanta, GA, USA
Faculty Chair
Evan Yu, MD
Fred Hutchinson Cancer Center, Seattle, WA, USA
More Information
- Tampa, FL
- Florida
More Information
- Scottsdale, AZ
- Arizona, Colorado, Nevada, New Mexico, Southern California, Utah
More Information
- Atlanta, GA
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Dallas, TX
- Arkansas, Kansas, Louisiana, Missouri, Oklahoma, Texas
More Information
- Philadelphia, PA
- Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Chicago, IL
- Illinois, Indiana, Iowa, Michigan, Minnesota, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin
More Information
- St Louis, MO
- Missouri
More Information
- San Diego, CA
- California, Nevada
More Information
- Orlando, FL
- Florida
More Information
- Seattle, WA
- Idaho, Montana, Northern California, Oregon, Washington, Wyoming
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of prostate cancer
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: apalutamide, darolutamide, enzalutamide, androgen deprivation therapy, docetaxel, abiraterone, and combinations of these drugs
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region